Read Mosby's 2014 Nursing Drug Reference Online
Authors: Linda Skidmore-Roth
Canada only Side effects:
italics
= common;
bold
= life-threatening
Nurse Alert
Brilinta
Func. class.:
Platelet inhibitor
Chem. class.:
ADP receptor antagonist
Reversibly bind to the platelet receptor, preventing platelet activation
Arterial thromboembolism prophylaxis in acute coronary syndrome (ACS) (unstable angina, acute MI), including in patients undergoing percutaneous coronary intervention (PCI)
Hypersensitivity, severe hepatic disease
Black Box Warning:
Bleeding, intracranial bleeding
Precautions:
Pregnancy (category C), breastfeeding, infants, neonates, children, GI bleeding, hepatic disease, abrupt discontinuation
Black Box Warning:
Coronary artery bypass graft surgery (CABG), surgery
• Adult:
PO
loading dose 180 mg with aspirin (usually 325 mg PO); then, give 90 mg bid with aspirin 75-100 mg/day, do not give maintenance doses of aspirin >100 mg/day
Available forms:
Tab 90 mg
•
May be taken without regard to food
•
Discontinue 5-7 days before surgery
•
May be crushed (90 mg tab) and mixed with purified water, 100 mg (PO) or 50 ml (NG)
CNS:
Headache, dizziness, fatigue
CV:
Hypertension, hypotension, chest pain, atrial fibrillation, bradyarrhythmias, syncope, ventricular pauses
GI:
Nausea, diarrhea
HEMA:
Serious, fatal bleeding
MISC:
Back pain, hyperuricemia, gynecomastia
RESP:
Dyspnea, cough
Absolute bioavailability 36%, protein binding (>99%), metabolism by CYP3A4, weak P-glycoprotein substrates and inhibitors, elimination for product and metabolite are hepatic and biliary, 84% excreted in feces, 26% in urine, half-life is 7 hr for ticagrelor, 9 hr for metabolite, maximum inhibition of platelet aggregation (IPA) effect 2 hr, maintained ≥8 hr, peak 1.5 hr product, 2.5 hr metabolite
Increase:
bleeding risk—CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, lopinavir, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, delavirdine, isoniazid, dalfopristin, quinupristin, tipranavir
Decrease:
ticagrelor action—CYP3A4 inducers (rifampin, dexamethasone, phenytoin, carBAMazepine, PHENobarbital)
Increase:
effect of—simvastatin lovastatin
Increase:
bleeding risk—NSAIDs, anticoagulants, platelet inhibitors
Increase or decrease:
digoxin
Increase:
serum creatinine
•
Thromboembolism:
Monitor CBC with differential with platelet count baseline and periodically during treatment
Black Box Warning:
Bleeding:
Assess for bleeding that may occur when aspirin is combined with this product, some bleeding can be fatal
•
Abrupt discontinuation:
Do not discontinue abruptly, may increase risk for MI, stent thrombosis, death
•
Storage at room temperature, in original container in dry place
•
Prevention of thromboembolism
•
To take only as prescribed, not to skip or double doses; if a dose is missed, to take next dose at scheduled time
Black Box Warning:
To notify prescriber of chills, fever, bruising, bleeding
•
Not to use any prescription, OTC products, herbs without approval of prescriber; products with aspirin, NSAIDs may cause bleeding
•
To notify all health care providers of product use
•
That product can be taken without regard to meals
•
That it may take longer for bleeding to stop
Canada only Side effects:
italics
= common;
bold
= life-threatening
Nurse Alert
Timentin
Func. class.:
Broad-spectrum antiinfective
Chem. class.:
Extended-spectrum penicillin, β-lactamase inhibitor
Interferes with cell-wall replication of susceptible organisms; osmotically unstable cell wall swells, bursts from osmotic pressure; clavulanate inhibits β-lactamase and protects against enzymatic degradation of ticarcillin
Respiratory, soft-tissue, and urinary tract infections; bacterial septicemia; effective for gram-positive cocci
(Staphylococcus aureus, Streptococcus faecalis, Streptococcus pneumoniae)
, gram-negative cocci
(Neisseria gonorrhoeae)
, gram-positive bacilli
(Clostridium perfringens, Clostridium tetani)
, gram-negative bacilli
(Bacteroides, Fusobacterium nucleatum, Escherichia coli, Proteus mirabilis, Salmonella, Morganella morganii, Proteus rettgeri, Enterobacter, Pseudomonas aeruginosa, Serratia);
and
Peptococcus, Peptostreptococcus
, and
Eubacterium
Neonates, hypersensitivity to penicillins
Precautions:
Pregnancy (B), hypersensitivity to cephalosporins, renal disease
• Adult ≥60 kg:
IV INF
3.1 g q4-6hr
• Adult <60 kg:
IV INF
200-300 mg/kg/day q4-6hr
• Child >60 kg:
IV INF
3.1 g q4-6hr
• Child <60 kg:
IV INF
300 mg/kg/day q4hr
• Full-term neonates/infants <3 mo (unlabeled):
IV
50 mg/kg q4hr for severe infections;
IV
50 mg/kg q6hr for mild to moderate infections
• Child ≥60 kg:
IV INF
3.1 g q6hr
• Child <60 kg:
IV INF
200 mg/kg/day q6hr
• Adult:
IV INF
loading dose 3.1 g; CCr 60 ml/min, 3.1 g q4hr; CCr 30-60 ml/min, 2 g q4hr; CCr 10-30 ml/min, 2 g q8hr; CCr <10 ml/min, 2 g q12hr; CCr <10 ml/min with hepatic dysfunction, 2 g q24hr
Available forms:
Inj 3 g ticarcillin, 0.1 g clavulanate; IV inf 3 g ticarcillin, 0.1 g clavulanate; powder for inj 3 g ticarcillin, 0.1 g clavulanate
•
Product after C&S, give ≥q1hr before bactericidal anti-infectives, change IV site q48hr
•
After diluting ≤3.1 g/13 ml of sterile water or NaCl (200 mg/ml), shake; may further dilute in ≥50-100 ml NS, D
5
W, or LR sol and run over 1/2 hr
Y-site compatibilities:
Allopurinol, amifostine, amikacin, anidulafungin, atropine, aztreonam, bivalirudin, bumetanide, ceFAZolin, cefepime, cefotaxime, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, cimetidine, clindamycin, cyclophosphamide, cycloSPORINE, dexamethasone, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOCEtaxel, DOPamine, DOXOrubicin liposome, doxycycline, enalaprilat, EPINEPHrine, esmolol, etoposide phosphate, famotidine, fenoldopam, filgrastim, fluconazole, furosemide, gemcitabine, gentamicin, granisetron, heparin, hydrocortisone, HYDROmorphone, imipenem/cilastatin, insulin, isoproterenol, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, melphalan, meperidine, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, milrinone, morphine, nitroglycerin, nitroprusside, norepinephrine, ondansetron, palonosetron, pantoprazole, PEMEtrexed, penicillin G potassium, perphenazine, phenylephrine, procainamide, propofol, propranolol, ranitidine, remifentanil, sargramostim, sodium bicarbonate, tacrolimus, teniposide, theophylline, thiotepa, tirofiban, tobramycin, vasopressin, verapamil, vinorelbine, voriconazole
CNS:
Anxiety,
seizures,
confusion, drowsiness
GI:
Nausea, vomiting, diarrhea;
increased AST, ALT; abdominal pain, glossitis, colitis,
pseudomembranous colitis, hepatotoxicity
HEMA:
Anemia, increased bleeding time,
bone marrow depression, granulocytopenia
INTEG:
Rash, urticaria,
toxic epidermal necrolysis,
pain at injection site
META:
Hypokalemia, hypernatremia
SYST:
Anaphylaxis, Stevens-Johnson syndrome,
overgrowth of organisms
IV:
Peak 30-45 min, duration 4 hr, half-life 64-68 min, excreted in urine
Increase:
bleeding—anticoagulants
Increase:
methotrexate level—methotrexate, uric acid, bilirubicin, BUN, creatining, alk, phos, LDH
Increase:
ticarcillin concentrations—probenecid, sulfipyrazone
Decrease:
antimicrobial effect of ticarcillin—tetracyclines, aminoglycosides IV, chloramphenicol, macrolides, sulfonamides
Decrease:
effect—
oral contraceptives,
erythromycin
False positive:
urine glucose, urine protein, Coombs’ test
Increase:
LFTs, sodium, eosinophils, INR bleeding time
Decrease:
Hgb, potassium, platelets, WBC, granulocytes
•
Infection: WBC, wound, temperature, sputum, urine, baseline and periodically
Pseudomembranous colitis:
diarrhea, abdominal pain, fever, fatigue, anorexia; possible anemia, elevated WBC count, low serum albumin; stop product; usually either vancomycin or IV metroNIDAZOLE is given
Serious skin reactions:
Stevens-Johnson syndrome, toxic epidermal necrolysis; anaphylaxis: wheezing, rash, laryngeal edema; have emergency equipment nearby
•
Hepatic studies: AST, ALT
•
Blood studies: WBC, RBC, Hct, Hgb, bleeding time, platelets, baseline and periodically
•
Renal studies: BUN, creatinine, sodium, potassium
•
Bowel pattern before, during treatment
•
Skin eruptions after administration of penicillin to 1 wk after discontinuing product
•
EPINEPHrine, suction, tracheostomy set, endotracheal intubation equipment
•
Storage of reconstituted sol 12-24 hr at room temp, or 3-7 days refrigerated
•
Therapeutic response: Resolution of infection
•
To report persistent diarrhea with blood, pus, mucous, or fever
•
That culture may be taken after completed course of medication
•
To report sore throat, fever, fatigue (may indicate superinfection); CNS effects (anxiety, depression, hallucinations, seizures)
•
To wear or carry emergency ID if allergic to penicillins
•
To use alternative birth control method instead of hormonal
Withdraw product, maintain airway, administer EPINEPHrine, O
2
, IV corticosteroids for anaphylaxis